We are pleased to now offer Monoclonal Antibody Treatment of COVID-19. This therapy is authorized by the FDA for the treatment of mild-to-moderate COVID-19 cases. The treatment that Family Hospital Systems will utilize is called Bamlanivimab. Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. This particular treatment is specifically directed against the spike protein of COVID-19 and is designed to block the virus’s attachment and entry into human cells.
This treatment will be offered to patients who have been diagnosed with COVID-19 and have comorbidities such as diabetes, COPD, heart disease, immunosuppression, obesity, or age. In order to limit potential exposure to our other patients, individuals receiving Monoclonal Antibody Treatment will be required to use a separate entrance to the treatment facility. This treatment is covered by all insurances, and patients will not incur out-of-pocket costs per the CARES Act.
“This use of this underutilized treatment means that we can more effectively alleviate hospital overcapacity while healing patients from this virus,” said Dr. Nathaniel Greenwood, Chief Medical Officer for Family Hospital Systems.
“We are proud to offer another way to combat this pandemic to our Greater Austin community”, said Dr. Henry Higgins, CEO of Family Hospital Systems.
With six locations in the Austin area, Family Hospital Systems is prepared to treat all medical emergencies with patient-focused care.